Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
The last earnings update was 23 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Trevi Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Trevi Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Trevi Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Trevi Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Trevi Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Trevi Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Trevi Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Trevi Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Trevi Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Trevi Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011. Ms. Good serves as Director at Rhythm Pharmaceuticals, Inc. since June 19, 2019. Ms. Good served as Chief Executive Officer and President of Penwest Pharmaceuticals Co. since June 2006 and November 23, 2005 respectively. Ms. Good served as the Chief Operating Officer of Penwest Pharmaceuticals from November 23, 2005 to June 2006; Chief Financial Officer from February 1997 to June 2006; Senior Vice President of Finance since 1997 and served as its Principal Accounting Officer and Company Secretary. She also served as Corporate Controller for Penford Corp. from 1993 to 1997. She led Penwest Pharmaceuticals Co.’s finance, human resources, corporate communications and information technology functions. Prior to joining Penwest, Ms. Good served as Corporate Controller and Corporate Director of Finance of Penford Corporation, Penwest’s former parent company, from 1993 to 1997. From 1987 to 1993, she served in a number of client management positions at Ernst & Young LLP, ultimately as audit Manager. She worked primarily with clients in the high technology, biotechnology and healthcare industries. She served as an Executive Director of Penwest Pharmaceuticals Co. since June 2006. She serves as a Director at Trevi Therapeutics, Inc. She served as Director of Juniper Pharmaceuticals, Inc. since September 11, 2017 until August 14, 2018. She served as a Director of XTL Biopharmaceuticals Ltd. since October 2008. In 2007, she received the Connecticut Technology Counsel’s Small Business Innovation and Leadership Award. She is a Certified Public Accountant in the state of Washington. Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987
Jennifer's compensation has been consistent with company performance over the past year, both up more than 20%.
Jennifer's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Trevi Therapeutics management team is about average.
Chief Financial Officer
Chief Commercial Officer & Head of International
Co-Founder & Chief Medical Officer
Chief Development Officer
Senior Vice President of CMC
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Trevi Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Member of Clinical Advisory Board
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Should You Take Comfort From Insider Transactions At Trevi Therapeutics, Inc. (NASDAQ:TRVI)?
View our latest analysis for Trevi Therapeutics Trevi Therapeutics Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Co-Founder Jennifer Good for US$113k worth of shares, at about US$10.00 per share. … In the last twelve months Trevi Therapeutics insiders were buying shares, but not selling. … From our data, it seems that Trevi Therapeutics insiders own 5.8% of the company, worth about US$5.2m.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company’s nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.